#United States #San Diego #ChemDiv #Clywedog #Barinthus

ChemDiv Enhances R&D Collaborations with Clywedog Therapeutics

ChemDiv, a distinguished global entity specializing in drug discovery solutions, has reaffirmed its commitment to support Clywedog Therapeutics in light of their recent merger with Barinthus Therapeutics. This strategic alliance, effective upon the completion of their merger, solidifies ChemDiv's role in enhancing research and development (R&D) activities tailored towards various metabolic disorders.

The Merger at a Glance

Clywedog Therapeutics, now officially moving forward as Clywedog Therapeutics, Inc., will operate under the ticker symbol CLYD on Nasdaq. The merger aims to integrate the expertise from Clywedog and Barinthus, combining cutting-edge developments in immunology and metabolism while focusing on critical areas such as Type 1 diabetes (T1D), Type 2 diabetes (T2D), and celiac disease. By merging their resources, the newly formed company anticipates advancing its clinical-stage candidates more aggressively and effectively.

ChemDiv’s Role

ChemDiv’s ongoing collaboration with Clywedog underscores its significance in research operations involving chemistry, computational analysis, and clinical pharmacology. Calling upon its robust platform that includes AI-driven pharmacology and accelerated CMC research, ChemDiv facilitates Clywedog’s transition of drug programs into clinical environments, building on its 2023-2024 developmental timeline. The integration of ChemDiv's medicinal chemistry and biology services has been pivotal in distinguishing groundbreaking inhibitors aimed specifically at enhancing islet cell proliferation and treating Type 2 diabetes.

• - MEN PPI inhibitors: These first-in-class compounds significantly contribute to islet cell proliferation, demonstrating promising therapeutic avenues in Type 2 diabetes treatments.
• - TYK2 inhibitors: Recognized as best-in-class entities, these compounds are instrumental in diminishing pro-inflammatory cytokine signaling, thereby safeguarding islet cell function and offering preventive solutions for Type 1 diabetes.

Driven by these innovations, ChemDiv’s involvement has propelled both programs successfully from the initial stages of discovery straight to clinical applications within a remarkable three-year timeframe.

Insights from Leadership

Roman Timakhov, the Research Director at ChemDiv, reflected positively on the merger. He stated, “We are incredibly proud to support the outstanding teams at both Barinthus Bio and Clywedog. As they unite their strengths in essential medical fields, our integrated platform — featuring AI-curated design, real-time medicinal chemistry, and extensive pharmacology and biology services — will help expedite the transformation of ambitious scientific hypotheses into viable, market-ready drugs.”

The Future

The merger is expected to culminate in the first half of 2026, paving the way for a stronger company to tackle pressing health issues. Barinthus Biotherapeutics, the company behind the recent merger, has built a reputation for developing immunotherapeutics designed to promote immune tolerance in autoimmune and inflammatory conditions. This transition, supported by ChemDiv, marks a decisive move towards enhancing healthcare around metabolic and autoimmune diseases, with a prominent focus on diabetes.

ChemDiv's distinctive offering, which includes an expansive library of over 12 million screening compounds, 2 trillion feasible chemistries, and AI-powered drug development services, reinforces its position as a premier discovery partner. As the industry evolves, ChemDiv’s role will be crucial in supporting this transformative journey for Clywedog Therapeutics and its future endeavors.

In summary, the merger not only signalizes a potent combination of expertise among the partnering companies but also sets the stage for breakthrough advancements in the treatment of significant health concerns like diabetes, ensuring that more innovative therapies make their way from laboratory to clinic, improving patient outcomes.

Conclusion

As ChemDiv and Clywedog Therapeutics march ahead following this merger, there is a shared excitement about the potential discoveries that await. Both companies' commitment to addressing complex health challenges through collaborative research places them at the forefront of biopharmaceutical innovation, reaffirming their roles as leaders in the fight against diabetes and other metabolic diseases.